Considering the potential for gene-based therapy in prostate cancer

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Therapeutic gene manipulation, particularly genome editing with CRISPR-Cas9, has advanced significantly, demonstrating potential for curing diseases.
• Prostate cancer research has a notable focus on gene therapy due to unique anatomical and immunological factors.
• Preclinical models and identified tumor antigens support gene therapy's application in prostate cancer.

Purpose of the Study:

• To review the current state and future potential of gene therapy in prostate cancer treatment.
• To highlight the advantages of prostate cancer for gene therapy interventions.
• To discuss promising gene therapy approaches like vaccines and CRISPR-Cas9-based CAR T cells.

Main Methods:

• Review of basic and clinical research on gene therapy and CRISPR-Cas9 applications.
• Evaluation of ongoing clinical trials in gene therapy for various diseases, with a focus on prostate cancer.
• Analysis of factors contributing to gene therapy's appeal in prostate cancer care.

Main Results:

• Gene therapy research, especially CRISPR-Cas9, shows potential for treating human diseases.
• Prostate cancer is a key area for gene therapy research due to specific patient and disease characteristics.
• Promising gene therapy strategies include vaccine-based and CRISPR-Cas9-assisted chimeric antigen receptor (CAR) T cell therapies.

Conclusions:

• Despite current limitations in achieving oncologically relevant outcomes, gene therapy holds significant promise for prostate cancer.
• Future research and clinical investigations are expected to establish gene therapy as a viable treatment option for prostate cancer.
• The combination of anatomical suitability, preclinical models, and targeted antigens makes prostate cancer a strong candidate for advanced gene therapies.